Arcutis Biotherapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Good morning. Serge Belanger, one of the senior healthcare analysts at Needham. I want to welcome you to our 22nd Annual Needham Healthcare Conference. And for our next session, we have Arcutis Biotherapeutics, and we have the CEO, Frank Watanabe, with us. He's going to give us an overview of the company. It's a company that launched their first product last year, since they've reported a string of positive Phase 3 results since then. And we got news this morning of another potential product approval later this year in December. So, I'll hand it over to Frank and he can give us a more detailed overview of the company.
Great. Thanks. Appreciate it, Serge. It's great seeing you.
So Arcutis is a seven-year-old company focused solely on medical dermatology. As you mentioned, we had our first product approved in July of last year. Topical roflumilast cream, the brand name is called ZORYVE, indicated for plaque psoriasis in patients
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
